Cencora, Inc. (COR) Stock Price & Analysis
Cencora, Inc. (COR) rose 2.00% to USD 279.57 as of June 9, 2026 at 22:34 UTC, according to Nexqual real-time market data.
COR last closed at USD 274.08; the session ranged USD 270.64–279.91 on volume of 1,011,542 shares. Market capitalization is $54.39B, with a 52-week range of USD 244.82–377.54 (NYQ). Source: Nexqual, June 9, 2026 at 22:34 UTC.
Key Statistics (as of June 9, 2026 at 22:34 UTC)
| Price | USD 279.57 |
|---|---|
| Change | ▲ 2.00% (up) |
| Previous Close | USD 274.08 |
| Open | USD 272.2 |
| Day Range | USD 270.64 – 279.91 |
| 52-Week Range | USD 244.82 – 377.54 |
| Volume | 1,011,542 shares |
| Market Cap | $54.39B |
| Exchange | NYQ |
Technical Analysis (COR)
Nexqual's technical model rates COR "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.78 (neutral) |
| vs SMA50 | Below (USD 291.33) |
| MACD | -4.45 (negative) |
Analyst Ratings (COR)
Wall Street analysts rate COR "Buy" based on 12 analysts, with a mean price target of USD 350.58 (range USD 280–412), per Nexqual as of June 9, 2026 at 22:34 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 350.58 |
| High Target | USD 412 |
| Low Target | USD 280 |
| Buy / Hold / Sell | 12 / 2 / 0 |
Earnings (COR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 4.35 |
| Revenue Estimate | $84.21B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.75 vs est 4.73 ▲ beat |
| 2025-12-31 | USD 4.08 vs est 4.04 ▲ beat |
| 2025-09-30 | USD 3.84 vs est 3.79 ▲ beat |
| 2025-06-30 | USD 4 vs est 3.84 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financials & Fundamentals (COR)
| Total Revenue | $328.68B |
|---|---|
| Revenue Growth (YoY) | +3.80% |
| Gross Margin | +3.80% |
| Operating Margin | +1.72% |
| Profit Margin | +0.78% |
| ROE | +107.13% |
| Debt / Equity | 420.99 |
| Current Ratio | 0.95 |
| Total Cash | $2.18B |
| Total Debt | $15.09B |
| Free Cash Flow | $-318.25M |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financial Health Score (COR)
Nexqual rates Cencora, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:34 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 4%, operating 2% |
| Balance Sheet | Critical — $2.18B cash vs $15.1B debt |
| Cash Flow | Weak — FCF negative: -$318M, burning cash |
| Efficiency | Strong — ROE 107%, ROA 3.5% |
Ownership (COR)
| Insider Ownership | +4.23% |
|---|---|
| Institutional Ownership | +98.59% |
| Shares Outstanding | 194.56M |
| Float | 184.01M |
| Short % of Float | +3.09% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Leadership (COR)
Cencora, Inc. is led by Robert P. Mauch Ph.D., PharmD (age 58), President, CEO & Director, per Nexqual as of June 9, 2026 at 22:34 UTC.
| President, CEO & Director | Robert P. Mauch Ph.D., PharmD (age 58) |
|---|---|
| Executive VP & CFO | James F. Cleary (age 62) |
| EVP and President of U.S. Pharmaceuticals & Animal Health | Richard Tremonte |
| EVP & President of International Business Group | Juan Guerra |
| Executive VP and Chief Strategy and M & A Officer | François Mandeville |
Major Backers & Investors (COR)
Notable institutional backers of Cencora, Inc. include Price (T.Rowe) Associates Inc, T. Rowe Price, FMR, LLC, according to Nexqual as of June 9, 2026 at 22:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 4.75% |
| T. Rowe Price | 4.66% |
| FMR, LLC | 3.44% |
| JPMorgan | 2.51% |
| Wellington Management | 2.34% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.1% |
| BlackRock | 11.54% |
| State Street | 5.91% |
| Geode Capital | 2.86% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
From Cencora, Inc.'s Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
- Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DLR | Digital Realty Trust, Inc. | USD 184.93 | ▼ 1% |
| EQIX | Equinix, Inc. | USD 1,059.84 | ▼ 1.95% |
| EXR | Extra Space Storage Inc | USD 148.23 | ▲ 2.01% |
| CPT | Camden Property Trust | USD 115.4 | ▲ 2.49% |
| ARE | Alexandria Real Estate Equities | USD 52.95 | ▲ 3.26% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:34 UTC. This page is informational and not investment advice.